BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Claturafenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Claturafenib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05355701-2156@assetmemo.bio
DTSTAMP:20261121T010142Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Claturafenib: Phase 1 readout est. (NCT05355701)
DESCRIPTION:Claturafenib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Learn About the Study Medicine Called PF-07799933 in People With 
 Advanced Solid Tumors With BRAF Alterations.\nEstimated primary completion
 : 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cla
 turafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05355701
URL:https://assetmemo.bio/drug/claturafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05538130-2156@assetmemo.bio
DTSTAMP:20261121T010142Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Claturafenib: Phase 1 readout est. (NCT05538130)
DESCRIPTION:Claturafenib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy 
 or in Combination in People With Advanced Solid Tumors\nEstimated primary 
 completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/claturafenib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05538130
URL:https://assetmemo.bio/drug/claturafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
